Results
Overall, 71 patients with first recurrence of uLMS were included in our
study. 19 patients (26.8%) received systematic therapy and 52 patients
(73.2%) received secondary cytoreductive surgery (SCS). In SCS subgroup
(n=52), a complete resection with no residual disease was reported in 47
patients (90.4%). 38.5% (20/52) patients
received non-genital organ
surgeries. 10 (19.2%) patients had received thoracic surgery because of
lung-only recurrences. Bowel, bladder surgery was performed in 8
(15.4%), 3 (5.8%) patients, respectively. 1 (1.9%) patient had
received liver surgery.
The median follow-up duration was 38.7 months (range: 2.7-317.6 months).
41 (57.7%) patients died during follow-up. 5-year OS for the entire
cohort was 52.9%. Patients experienced first recurrence after initial
diagnoses within 12 months (n=24) had a worse 5-year OS than those after
12 months (n=47) (17.0% vs 69.1%, P<0.001). 5-year OS for
the SCS and non-SCS subgroup was 62.0% and 28.0%, respectively
(P<0.001). Multivariate analysis showed time to fist
recurrence within 12 months (HR=4.60, 95% CI: 1.49-14.4, P = 0.008) was
an independent predictor of decreased 5-year OS in SCS subgroup.